MUSK and myasthenia gravis: Within the MuSK Ab+ gMG subgroup, mean baseline MG-‍ADL score was numerically greater in those treated with rozanolixizumab 7 mg/kg compared with those receiving rozanolixizumab 10 mg/kg.